First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

Cancer Immunology, Immunotherapy : CII
Bastian SchillingBenjamin Weide

Abstract

Inhibition of the mitogen-activated protein kinase (MAPK) pathway as well as programmed death 1 receptor (PD-1) blockade was shown to prolong overall survival (OS) in patients with advanced B-Raf proto-oncogene (BRAF)-mutant melanoma. However, due to the lack of head-to-head trials, it remains unclear if one of these therapeutic approaches should be preferred in first-line therapy. Here, we present a retrospective analysis comparing anti-PD-1 monotherapy with BRAF/MAPK/ERK kinase (MEK) combined inhibition used as first-line agents in a real-world clinical setting. Clinical data, routine blood counts and lactate dehydrogenase (LDH) levels of 301 patients with unresectable or metastatic melanoma harboring an activating mutation in BRAF (V600E/K) were included. Of these, 106 received anti-PD-1 antibodies, while 195 patients were treated with a selective BRAF inhibitor combined with an MEK inhibitor as palliative first-line therapy. Patients were sub-grouped according to previously described predictive and prognostic markers. OS was significantly longer in patients receiving anti-PD-1 monotherapy compared to patients receiving combined MAPK inhibitors. Subsequent therapies were comparable among these groups. The difference in OS wa...Continue Reading

References

Aug 1, 1996·Controlled Clinical Trials·M Schemper, T L Smith
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles M BalchVernon K Sondak
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Nov 23, 2013·Cancer Discovery·Eliezer M Van AllenUNKNOWN Dermatologic Cooperative Oncology Group of Germany (DeCOG)
Sep 30, 2014·The New England Journal of Medicine·Georgina V LongKeith Flaherty
Sep 30, 2014·The New England Journal of Medicine·James LarkinAntoni Ribas
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jun 4, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D MassiM Mandalà
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R DummerUNKNOWN ESMO Guidelines Committee
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benjamin WeideJedd D Wolchok
Nov 16, 2016·Journal of Immunotherapy·Douglas B JohnsonRyan J Sullivan
Nov 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adil I DaudOmid Hamid
Jun 27, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Dirk SchadendorfCaroline Robert
Sep 16, 2017·Current Opinion in Oncology·Inês P Silva, Georgina V Long
Oct 11, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georgina V LongKeith T Flaherty
Dec 2, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Katrin Schaper-GerhardtRalf Gutzmer

❮ Previous
Next ❯

Citations

Jan 7, 2020·Expert Review of Anticancer Therapy·Dimitrios C ZiogasHelen Gogas
Jan 3, 2020·Current Opinion in Oncology·Pauline TétuCéleste Lebbe
Dec 1, 2020·Deutsche medizinische Wochenschrift·Oana-Diana Persa, Cornelia Mauch
Oct 14, 2020·The Journal of Investigative Dermatology·Florence PoizeauAlain Dupuy
Mar 19, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sarah KnispelLisa Zimmer
Mar 26, 2021·American Journal of Clinical Dermatology·Dimitrios C ZiogasHelen Gogas
Feb 9, 2020·Annales de dermatologie et de vénéréologie·C Gaudy-Marqueste

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Keith T FlahertyJeffrey Weber
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Selma UgurelClaus Garbe
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Selma UgurelClaus Garbe
© 2022 Meta ULC. All rights reserved